Tiziana Life Sciences PLC Sponsored ADR Stock price
Is Tiziana Life Sciences PLC Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.
StocksGuide Premium
StocksGuide Unlimited
Key metrics
📘 Market Capitalization
📈 What is it?
Market capitalization shows how much a company is currently worth on the stock market.
🧮 How is it calculated?
🏛️ Why is it important?
It helps classify companies by size (Large, Mid, Small Cap) and indicates their market presence and relative stability.
🧮 Calculation
🎯 What does this mean for investors?
- Large-cap companies tend to be more stable, often pay dividends, but may grow more slowly.
- Smaller firms may offer higher growth potential but come with more volatility.
- Market capitalization is a useful indicator of company size — but not a measure of whether a stock is undervalued or overvalued.
📘 Enterprise Value (EV)
📈 What is it?
Enterprise Value represents the total cost to acquire a company — including its debt and excluding its cash reserves.
🧮 How is it calculated?
(= Market Cap + Net Debt)
🏛️ Why is it important?
EV gives a more complete picture of a company's value than market cap alone and is used in key valuation ratios like EV/FCF or EV/Sales.
🧮 Calculation
🎯 What does this mean for investors?
- Enterprise Value shows the true cost of buying a company, including all financial obligations.
- It is more accurate than just looking at market cap, especially when comparing companies with different levels of debt or cash.
- Professional investors prefer EV-based multiples because they better reflect the company’s full financial footprint.
📘 Net Debt
📈 What is it?
Net Debt shows how much debt remains after subtracting a company’s available cash reserves.
🧮 How is it calculated?
🏛️ Why is it important?
It indicates how dependent a company is on borrowed money and how easily it can service its debt in the short term.
🧮 Calculation
🎯 What does this mean for investors?
- Low or negative net debt signals financial strength and flexibility.
- Companies with strong cash positions are better positioned in crises.
- High net debt increases financial risk — especially in environments with rising interest rates or economic downturns.
📘 Cash
📈 What is it?
Cash represents all liquid assets a company can access immediately — including cash, bank deposits, and short-term investments.
🧮 How is it calculated?
🏛️ Why is it important?
It reflects a company’s financial flexibility and resilience — enabling investments, buybacks, or buffer in downturns.
🧮 Calculation
🎯 What does this mean for investors?
- A strong cash position means greater room for maneuver and crisis resistance.
- Cash-rich companies can invest, pay down debt, or repurchase shares.
- But excess idle cash might indicate a lack of growth opportunities.
📘 Shares Outstanding
📈 What is it?
Shares outstanding represent the total number of a company’s shares currently held by investors — excluding treasury stock.
🧮 How is it calculated?
🏛️ Why is it important?
It’s the basis for key metrics like Earnings Per Share (EPS), Market Capitalization, or the Price/Earnings ratio (P/E).
🧮 Calculation
🎯 What does this mean for investors?
- Fewer shares in circulation typically increase earnings per share — making each share more valuable.
- Share buybacks reduce the number of shares and boost per-share metrics.
- Issuing new shares does the opposite — diluting shareholder value and lowering per-share figures.
📘 Price-to-Earnings Ratio (P/E)
📈 What is it?
The P/E ratio shows how many times a company's earnings per share are reflected in its current share price — in other words, how "expensive" the stock appears relative to its profits.
🧮 How is it calculated?
🏛️ Why is it important?
The P/E ratio is one of the most widely used valuation metrics. It helps investors assess whether a stock appears cheap or expensive compared to its earnings power.
🧮 Calculation
📊 P/E (TTM) = Based on earnings from the last 12 months (Trailing Twelve Months):🎯 What does this mean for investors?
- A low P/E may indicate undervaluation — or signal underlying issues.
- A high P/E may reflect strong growth expectations — or an overvalued stock.
📘 Price-to-Sales Ratio (P/S)
📈 What is it?
The P/S ratio shows how much investors are paying for $1 of the company’s revenue – regardless of profitability.
🧮 How is it calculated?
🏛️ Why is it important?
P/S is especially useful for evaluating growth companies or businesses not yet profitable. It reflects how the market values the company’s sales.
🎯 What does this mean for investors?
- A low P/S may indicate undervaluation — or low profitability.
- A high P/S can reflect strong growth expectations — or excessive optimism.
- Especially helpful when evaluating companies where profits are low, volatile, or negative.
📘 Enterprise Value to Sales (EV/Sales)
📈 What is it?
EV/Sales shows how much investors are paying for $1 of revenue — considering not just equity, but also debt and cash. It’s the capital structure–adjusted version of the P/S ratio.
🧮 How is it calculated?
🏛️ Why is it important?
It’s ideal for comparing companies with different levels of debt. It reflects a company's true cost relative to its revenue.
🎯 What does this mean for investors?
- EV/Sales allows for capital structure–neutral company comparisons.
- A lower ratio may indicate undervaluation; a higher one may signal strong growth expectations or overvaluation.
- Especially helpful when evaluating high-growth companies with low or negative earnings.
📘 Enterprise Value to Free Cash Flow (EV/FCF) | ex SBC
📈 What is it?
EV/FCF compares a company’s enterprise value with its free cash flow. The metric therefore shows the multiple of current free cash flow at which a company is valued. EV/FCF ex SBC additionally accounts for stock-based compensation (SBC). While SBC does not represent a direct cash outflow, issuing shares as compensation can dilute existing shareholders. Therefore, SBC is deducted from free cash flow in this adjusted version.
🧮 How is it calculated?
EV/FCF ex SBC = Enterprise Value ÷ (Free Cash Flow (TTM) − SBC)
🏛️ Why is it important?
EV/FCF provides a valuation based on free cash flow and therefore complements earnings-based valuation metrics such as the P/E ratio. The ex SBC version additionally accounts for the economic impact of stock-based compensation and provides a more conservative view from a shareholder perspective.
🧮 Calculation
🎯 What does this mean for investors?
- A low EV/FCF means that enterprise value is low relative to current free cash flow. The reasons should always be considered in the context of the company and its industry.
- A high EV/FCF means that enterprise value is high relative to current free cash flow. This can, for example, reflect high growth expectations or temporarily weak cash generation.
- When SBC is positive and adjusted free cash flow remains positive, EV/FCF ex SBC is generally higher than the standard EV/FCF.
- The metric is particularly useful for companies with relatively stable and predictable cash flows.
- If free cash flow is negative or very low, EV/FCF has limited usefulness and should not be interpreted like a standard valuation multiple.
📘 Price-to-Book Ratio (P/B)
📈 What is it?
The P/B ratio compares a company’s market value to its book value — showing how much investors are paying for each dollar of net assets.
🧮 How is it calculated?
🏛️ Why is it important?
P/B is commonly used for asset-heavy industries like banks or industrials. It helps assess whether a stock is trading above or below its net asset value.
🧮 Calculation
🎯 What does this mean for investors?
- A P/B below 1 may signal undervaluation — or weak profitability.
- A P/B above 1 implies the market expects future value creation (e.g., brand, IP, growth).
- Best used for companies with tangible assets and strong balance sheets.
📘 Equity Ratio
📈 What is it?
The equity ratio indicates what portion of a company’s total assets is financed by shareholders’ equity – in other words, how much it relies on its own capital.
🧮 How is it calculated?
🏛️ Why is it important?
A high equity ratio reflects financial strength and stability, especially during downturns. It’s a key indicator of a company’s solvency and long-term risk profile.
🧮 Calculation
🎯 What does this mean for investors?
- Companies with high equity ratios are generally more resilient and less dependent on external debt.
- Low equity ratios can signal higher risk or aggressive financial strategies.
- Important: Always assess the equity ratio in combination with the return on equity (ROE). This shows not just how stable the company is – but also how efficiently it uses shareholder capital.
📘 Return on Equity (ROE)
📈 What is it?
Return on equity (ROE) shows how efficiently a company uses its shareholders’ equity to generate profit. In other words: how much net income is earned per dollar of equity.
🧮 How is it calculated?
🏛️ Why is it important?
ROE is a core profitability metric. It helps investors understand whether a company delivers attractive returns on the capital provided by its shareholders.
🎯 What does this mean for investors?
- A high ROE indicates that the company is using its capital efficiently and profitably.
- It’s especially meaningful for capital-intensive businesses or firms with high equity bases.
- Important: A very high ROE can also result from high debt levels – always interpret it alongside the equity ratio to assess financial health.
📘 Return on Capital Employed (ROCE)
📈 What is it?
ROCE measures how efficiently a company generates profits from its total capital – including both equity and interest-bearing debt.
🧮 How is it calculated?
It evaluates the return on all capital employed, regardless of how it’s financed.
🏛️ Why is it important?
ROCE is ideal for comparing companies with different financing structures. It shows how well management uses capital to create value for both shareholders and creditors.
🧮 Calculation
🎯 What does this mean for investors?
- A high ROCE means the company uses its capital efficiently – regardless of whether it's funded by debt or equity.
- The higher the ROCE compared to peers, the more value the company creates with its invested capital.
- Especially relevant for capital-intensive sectors like industrials, energy, or infrastructure.
📘 Return on Invested Capital (ROIC)
📈 What is it?
ROIC measures how efficiently a company generates returns from the capital invested in its core operations – regardless of whether the capital comes from equity or debt.
🧮 How is it calculated?
- NOPAT = Net Operating Profit After Taxes
- Invested Capital = Operating assets minus non-interest-bearing liabilities
🏛️ Why is it important?
ROIC is one of the most accurate indicators of capital efficiency. Unlike return on equity, it is not distorted by leverage and shows how much value is created for all capital providers.
🧮 Calculation
🎯 What does this mean for investors?
- A high ROIC shows how effectively a company uses the capital that is truly invested in its core operations.
- Unlike ROCE, ROIC focuses only on the capital that is actively used to run the business – and that requires a return (i.e. interest-bearing).
- Especially useful when comparing companies with large amounts of excess cash or non-interest-bearing liabilities – giving a more realistic picture of capital efficiency.
📘 Leverage Ratio (Debt-to-Equity)
📈 What is it?
The leverage ratio indicates how much a company relies on interest-bearing debt (such as loans and bonds) relative to its shareholders’ equity.
🧮 How is it calculated?
🏛️ Why is it important?
This ratio helps assess a company’s financial structure and risk profile. High leverage can enhance returns – but also increases exposure to interest rate changes and financial stress.
🧮 Calculation
🎯 What does this mean for investors?
- A low leverage ratio signals financial strength and independence.
- A higher ratio can improve returns in good times but increases risk during downturns or rising interest rate periods.
- 👉 Always interpret in the context of industry, capital intensity, and interest rate environment.
📘 SBC | in % Revenue
📈 What is it?
SBC (Stock-Based Compensation) refers to equity-based compensation granted by a company to its employees and executives. The percentage shows SBC relative to revenue.
🧮 How is it calculated?
SBC as % of Revenue = (SBC ÷ Revenue) × 100
🏛️ Why is it important?
Stock-based compensation is a real cost factor for shareholders. It can increase the number of shares outstanding and therefore dilute existing shareholders. The percentage of revenue shows how heavily a company relies on equity-based compensation and how significant this form of compensation is relative to the size of the business.
🎯 What does this mean for investors?
- A lower figure is generally positive: Stock-based compensation is relatively small compared with the company's revenue.
- A high figure can indicate greater reliance on stock-based compensation and a higher potential risk of dilution. However, it is also important to consider whether the company offsets dilution through share buybacks.
- The trend over time should also be considered. A high but declining percentage presents a different picture from a persistently high or increasing percentage.
- A single-digit SBC-to-revenue ratio is not unusual among many growth-oriented and technology companies.
📘 SBC as % of FCF
📈 What is it?
SBC (Stock-Based Compensation) refers to equity-based compensation granted by a company to its employees and executives. The percentage shows SBC relative to free cash flow (FCF).
🧮 How is it calculated?
SBC as % of FCF = (SBC ÷ Free Cash Flow) × 100
🏛️ Why is it important?
Stock-based compensation is a real cost factor for shareholders. It can increase the number of shares outstanding and therefore dilute existing shareholders. The percentage of free cash flow shows how significant SBC is relative to the cash generated by the company. Since SBC is non-cash compensation, it is typically not deducted as a cash outflow when calculating FCF.
🎯 What does this mean for investors?
- A lower value is generally favorable. Stock-based compensation is relatively small compared with the company's cash generation.
- A high value means that SBC represents a significant portion of the company's reported free cash flow, even though SBC itself is non-cash.
- The higher the value, the more significant SBC can be as an economic cost to shareholders, particularly when it results in share dilution.
📘 SBC Growth 1Y
📈 What is it?
SBC Growth 1Y shows how much a company's stock-based compensation has changed compared to the previous year.
🧮 How is it calculated?
🏛️ Why is it important?
SBC Growth shows whether stock-based compensation is becoming more or less significant for shareholders. If SBC increases significantly, it can lead to greater shareholder dilution over time. At the same time, SBC is a non-cash expense that reduces earnings on the income statement but is added back in the cash flow statement.
🧮 Calculation
🎯 What does this mean for investors?
- A high positive value is generally negative, as rising SBC can increase the burden on shareholders, particularly through potential dilution.
- What matters is whether the development of SBC is sustainable over the long term. Some level of SBC is common among many growth and technology companies.
📘 Share Count Growth 1Y
📈 What is it?
Share Count Growth 1Y shows how much the number of shares outstanding has increased or decreased over a one-year period.
🧮 How is it calculated?
🏛️ Why is it important?
The number of shares determines how many shares the company's earnings and assets are distributed across. If the share count decreases, existing shareholders' relative ownership increases. If it increases, existing shareholders are diluted. The metric therefore makes dilution and share buybacks directly visible.
🧮 Calculation
🎯 What does this mean for investors?
- A negative value is generally positive, as the number of shares outstanding is decreasing.
- A positive value indicates dilution of existing shareholders.
- A declining share count is not automatically positive: It also matters at what price the shares are repurchased and how the buybacks are financed.
📘 Shareholder Yield
📈 What is it?
Shareholder Yield measures how much capital a company returns to shareholders through dividends and share buybacks, relative to its market capitalization. It goes beyond dividend yield by also including share buybacks.
🧮 How is it calculated?
🏛️ Why is it important?
Dividend yield only tells part of the story. When a company buys back shares and the share count falls, each existing shareholder owns a larger part of the company. When the share count rises, for example through stock-based compensation or new share issuance, existing shareholders are diluted. Shareholder Yield combines both into one metric.
🧮 Calculation
🎯 What does this mean for investors?
- A higher Shareholder Yield indicates more capital being returned to shareholders.
- A negative value means the company issued more new shares than its dividends and buybacks make up for.
- Share buybacks are most beneficial when shares are repurchased at attractive valuations.
- Investors should also consider whether dividends and buybacks are sustainable over time.
📘 Revenue
📈 What is it?
Revenue shows how much a company earns in total from selling its products and services – the gross income before any costs are deducted.
🧮 How is it calculated?
🏛️ Why is it important?
Revenue is one of the key figures to assess a company’s size, market position, and growth potential.
🧮 Calculation
🎯 What does this mean for investors?
- Growing revenue indicates rising demand and can be an early signal of future earnings growth.
- Comparing actual and expected revenue reveals trends in the market environment and analyst sentiment.
- Note: Strong revenue alone isn’t enough – margins and profitability matter just as much.
📘 EBITDA
📈 What is it?
EBITDA stands for “Earnings Before Interest, Taxes, Depreciation, and Amortization.” It reflects a company’s operating profit before the effects of financing, taxes, and accounting depreciation.
🧮 How is it calculated?
🏛️ Why is it important?
EBITDA is widely used to evaluate a company’s operating performance – especially across capital-intensive sectors or international comparisons.
🧮 Calculation
🎯 What does this mean for investors?
- A high or growing EBITDA indicates strong operational profitability – independent of taxes, interest, or accounting methods.
- It’s especially useful for comparing companies across sectors or geographies.
- Important: EBITDA is not a net income figure – it excludes key costs like depreciation and interest.
📘 EBIT
📈 What is it?
EBIT stands for “Earnings Before Interest and Taxes.” It reflects a company’s operating profit after depreciation, but before interest and tax expenses.
🧮 How is it calculated?
🏛️ Why is it important?
EBIT is a core profitability metric that shows how well the company performs in its main business operations – independent of capital structure and tax environment.
🧮 Calculation
🎯 What does this mean for investors?
- A high EBIT indicates strong profitability from the company’s core business – before financial and tax effects.
- It allows better comparison between companies with different debt levels or tax structures.
- Compared to EBITDA, EBIT already accounts for depreciation and reflects capital intensity more clearly.
📘 Net Income
📈 What is it?
Net income is the company’s total profit – the amount left after all expenses, taxes, interest, and depreciation have been deducted.
🧮 How is it calculated?
🏛️ Why is it important?
Net income is the most comprehensive measure of a company’s profitability – showing how much actual profit remains after all business and financing costs.
🧮 Calculation
🎯 What does this mean for investors?
- Growing net income indicates that the company is managing all of its costs efficiently.
- It directly influences valuation metrics like P/E ratio and the company’s dividend capacity.
- Over time, net income trends reveal how resilient and profitable the business model really is.
📘 Free Cash Flow (FCF) | ex SBC
📈 What is it?
Free cash flow shows how much cash remains after a company has covered its operating and capital expenditures. FCF ex SBC additionally deducts stock-based compensation (SBC) to adjust the cash flow for the effect of non-cash SBC.
🧮 How is it calculated?
Free Cash Flow ex SBC = Operating Cash Flow − SBC − Capital Expenditures (CAPEX)
🏛️ Why is it important?
FCF reflects a company’s actual financial strength – independent of reported accounting earnings. It shows how much flexibility a company has for dividends, share buybacks, or debt reduction. FCF ex SBC also deducts stock-based compensation and shows how much cash generation remains after SBC.
🧮 Calculation
🎯 What does this mean for investors?
- High free cash flow indicates that a company has strong financial strength – independent of reported earnings.
- It is often a solid basis for sustainable dividends and share buybacks.
- Declining FCF can be a warning sign, even if reported earnings remain stable.
📘 Revenue Growth
📈 What is it?
Revenue growth shows how much a company’s sales have changed compared to the previous year – both on a trailing basis (TTM) and based on forward projections.
🧮 How is it calculated?
Forward = (Expected revenue ÷ Revenue in prior year − 1) × 100
Forward growth is based on analyst estimates for the current fiscal year.
🏛️ Why is it important?
Rising revenue signals growing demand, business expansion, and market share gains – especially important for growth-oriented companies.
🎯 What does this mean for investors?
- Growth is the engine of long-term value creation – especially in tech and growth sectors.
- What matters is not just current growth, but its sustainability.
- Forward projections reflect whether analysts expect continued momentum – or a slowdown.
📘 EBITDA Growth
📈 What is it?
EBITDA growth shows how much a company’s operating profit (before interest, taxes, depreciation, and amortization) has increased or decreased compared to the previous year.
🧮 How is it calculated?
Forward = (Expected EBITDA ÷ EBITDA from prior year − 1) × 100
The forward estimate is based on analyst projections for the current fiscal year.
🏛️ Why is it important?
Growing EBITDA indicates improving operational profitability – regardless of financing or accounting effects.
🧮 Calculation
🎯 What does this mean for investors?
- Strong EBITDA growth signals operational efficiency and scalability – especially during growth phases.
- EBITDA growth can be an early indicator of margin and earnings expansion – but should be assessed alongside revenue and EBIT.
📘 EBIT Growth
📈 What is it?
EBIT growth shows how much a company’s operating profit (after depreciation, but before interest and taxes) has increased compared to the previous year.
🧮 How is it calculated?
Forward = (Expected EBIT ÷ EBIT from prior year − 1) × 100
The forward estimate is based on analyst projections for the current fiscal year.
🏛️ Why is it important?
EBIT growth is a direct indicator of a company’s business performance – taking into account capital intensity through depreciation.
🧮 Calculation
🎯 What does this mean for investors?
- Rising EBIT signals improving operating profitability – even after accounting for depreciation.
- It’s especially important for evaluating companies with significant capital expenditures.
- Combined with revenue and EBITDA growth, EBIT growth provides a well-rounded view of operational progress.
📘 Net Income Growth
📈 What is it?
Net income growth shows how much a company’s bottom-line profit has increased or decreased compared to the previous year – both on a trailing basis (TTM) and based on analyst projections.
🧮 How is it calculated?
Forward = (Expected net income ÷ Net income from prior year − 1) × 100
The forward estimate reflects analysts’ expectations for the current fiscal year.
🏛️ Why is it important?
Net income is the ultimate measure of profitability. Growing net income signals stronger efficiency, cost control, and sustainable earnings power.
🧮 Calculation
🎯 What does this mean for investors?
- Stronger net income boosts valuation, dividend potential, and investor confidence.
- If profits stall while revenue grows, it may signal margin pressure.
📘 Free Cash Flow Growth
📈 What is it?
Free cash flow (FCF) growth shows how a company’s available cash – after covering operating expenses and capital expenditures – has changed compared to the previous year.
🧮 How is it calculated?
🏛️ Why is it important?
Free cash flow reflects real financial strength. Growing FCF indicates more flexibility for dividends, share buybacks, and reinvestment.
🧮 Calculation
🎯 What does this mean for investors?
- Declining FCF may point to rising investments, increasing costs, or weaker operating performance.
- Especially for dividend investors, FCF growth is critical – since dividends are paid from actual available cash.
- A negative trend isn't always bad, but it deserves closer attention.
📘 Gross Margin
📈 What is it?
Gross margin shows how much of a company’s revenue remains after deducting the direct costs of goods sold (like materials and production). It represents the company’s “raw profit” before fixed costs, taxes, and interest.
🧮 How is it calculated?
Or simply: Gross Margin = Gross Profit ÷ Revenue × 100
🏛️ Why is it important?
Gross margin indicates how efficiently a company can produce or procure what it sells. It is a key measure of product-level profitability and pricing power.
🎯 What does this mean for investors?
- A high gross margin suggests strong pricing power and efficient production.
- Falling margins may signal rising input costs or competitive pressure.
- Compared to peers, gross margin offers insights into the quality of a business model.
📘 EBITDA Margin
📈 What is it?
The EBITDA margin shows how much of a company’s revenue remains as operating profit before interest, taxes, depreciation, and amortization.It reflects operating efficiency without being distorted by financing or accounting factors.
🧮 How is it calculated?
🏛️ Why is it important?
The EBITDA margin reveals how much operating income a company generates per dollar of revenue – independent of capital structure and tax effects.
🎯 What does this mean for investors?
- A high EBITDA margin reflects strong core profitability – before accounting distortions.
- It allows for effective comparisons across companies and sectors.
- A stable or growing margin signals efficient cost control and business scalability.
📘 EBIT Margin
📈 What is it?
The EBIT margin shows what percentage of revenue remains as operating profit after depreciation but before interest and taxes.
🧮 How is it calculated?
🏛️ Why is it important?
The EBIT margin reflects a company’s core profitability while accounting for capital intensity (e.g. machinery, infrastructure). It’s especially useful for comparing businesses with different levels of depreciation.
🎯 What does this mean for investors?
- A high EBIT margin shows that the company remains efficient even after factoring in depreciation.
- It’s especially relevant for capital-intensive industries.
- Stable or rising EBIT margins over time are a strong indicator of pricing power and business quality.
📘 Net Margin
📈 What is it?
Net margin shows how much of a company’s revenue remains as bottom-line profit after deducting all costs, interest, taxes, and depreciation.
🧮 How is it calculated?
🏛️ Why is it important?
Net margin reflects a company’s overall efficiency – across operations, financing, and taxation. It shows how much actual profit is generated from each dollar of revenue.
🎯 What does this mean for investors?
- A high net margin means the company is not only strong operationally but also manages financing and taxes efficiently.
- Peer comparisons reveal business quality and competitiveness.
- Declining margins despite revenue growth can be a red flag for rising costs or inefficiencies.
📘 Free Cash Flow Margin | ex SBC
📈 What is it?
The Free Cash Flow Margin shows how much free cash flow a company generates relative to its revenue. In simplified terms, free cash flow is calculated as operating cash flow minus capital expenditures. The Free Cash Flow Margin ex SBC additionally accounts for stock-based compensation (SBC). While SBC does not represent a direct cash outflow, issuing shares as compensation can dilute existing shareholders. Therefore, SBC is deducted from free cash flow in this adjusted metric.
🧮 How is it calculated?
Free Cash Flow Margin ex SBC = (Free Cash Flow − SBC) ÷ Revenue × 100
🏛️ Why is it important?
The Free Cash Flow Margin shows how efficiently a company converts its revenue into free cash flow. Strong free cash flow can provide financial flexibility for dividends, share buybacks, debt repayment, or further investments. The ex SBC version additionally accounts for the economic impact of stock-based compensation and therefore provides a more conservative view of cash generation from a shareholder perspective.
🎯 What does this mean for investors?
- A high Free Cash Flow Margin shows that a company converts a high proportion of its revenue into free cash flow.
- This can provide greater financial flexibility for dividends, share buybacks, debt repayment, or investments.
- The Free Cash Flow Margin ex SBC additionally accounts for potential shareholder dilution from stock-based compensation.
- The long-term trend is particularly important. Declining margins can, for example, result from higher investments, changes in working capital, or weaker operating performance.
📘 Earnings per share (EPS)
📈 What is it?
Earnings per Share (EPS) shows how much profit is attributable to a single share – and is one of the most important metrics for evaluating a company's performance.
🧮 How is it calculated?
The diluted share count reflects potential new shares that could be issued through options, convertible bonds, or other rights.
🏛️ Why is it important?
EPS is the basis for many key valuation metrics like P/E ratio, PEG ratio, or payout ratio. It enables comparisons of profitability across companies, regardless of their size.
🧮 Calculation
🎯 What does this mean for investors?
- EPS captures per-share profitability and is especially useful for comparisons over time or with analyst estimates.
- Rising EPS may signal consistent growth or share buybacks.
- Important: Always use diluted EPS for more realistic valuations – especially in companies with stock-based compensation.
📘 Free cash flow per share (FCF per share)
📈 What is it?
Free Cash Flow per Share shows how much free cash flow a company generates per outstanding share – after investments, but before dividends or debt repayments.
🧮 How is it calculated?
Free cash flow is calculated as operating cash flow minus capital expenditures (CapEx).
🏛️ Why is it important?
FCF per Share reveals how much real cash is available per share – useful for dividends, buybacks, or reducing debt. Unlike net income, free cash flow is harder to manipulate and often seen as a more reliable metric.
🧮 Calculation
🎯 What does this mean for investors?
- High FCF per share signals strong financial flexibility.
- It shows how much capital the company can effectively reinvest or return to shareholders.
- Particularly relevant for dividend payers and capital-efficient businesses.
📘 Short interest
📈 What is it?
Short interest indicates how many shares of a company are currently sold short – that is, borrowed and sold by investors who expect the price to decline.
🧮 How is it calculated?
It reflects the percentage of a company’s shares that are being shorted relative to the total shares available.
🏛️ Why is it important?
Short interest serves as a sentiment indicator: A high value may signal skepticism or bearish expectations – but also increases the potential for a short squeeze if prices rise unexpectedly.
🧮 Calculation
🎯 What does this mean for investors?
- Low short interest usually indicates market confidence in the company.
- High short interest can be a warning sign – or an opportunity if sentiment shifts.
- Especially relevant in volatile markets or ahead of key earnings releases.
📘 Employees
📈 What is it?
The employee count shows how many people a company employs worldwide – offering insights into its size, structure, and business model.
🧮 How is it calculated?
🏛️ Why is it important?
It helps assess operational scale, labor intensity, and cost structure. Combined with revenue and profit, it enables key metrics like revenue per employee or productivity.
🧮 Calculation
🎯 What does this mean for investors?
- A high headcount can signal operational complexity – but also significant growth capacity.
- Revenue per employee is a key indicator of efficiency.
- Especially useful for comparing tech, industrial, or service-heavy companies.
📘 Revenue per employee
📈 What is it?
Revenue per employee indicates how much revenue a company generates on average per employee – a key measure of efficiency and productivity.
🧮 How is it calculated?
The employee count is typically taken from the most recent annual report.
🏛️ Why is it important?
This metric helps compare business models – especially between labor-intensive and technology-driven companies. A high value suggests automation, operational efficiency, or strong value creation per head.
🎯 What does this mean for investors?
- A high revenue per employee indicates a scalable and margin-strong business model.
- A low figure may reflect labor-intensive operations or lower value-add.
- Especially helpful when comparing tech companies to industrial or service sectors.
Tiziana Life Sciences PLC Sponsored ADR Stock Analysis
Analyst Opinions
8 Analysts have issued a Tiziana Life Sciences PLC Sponsored ADR forecast:
Analyst Opinions
8 Analysts have issued a Tiziana Life Sciences PLC Sponsored ADR forecast:
Tiziana Life Sciences PLC Sponsored ADR Events
Past Events
|
NOV
9
Special Call - Tiziana Life Sciences Ltd
9 days ago
|
StocksGuide Free
Tiziana Life Sciences PLC Sponsored ADR — Special Call - Tiziana Life Sciences Ltd
1. Management Discussion
Well, welcome, everybody. Today, we're here. It's a lovely day, November 9. We're here to talk about our Phase II results in the INFORM-MS trial, which was a Phase II placebo-controlled double-blind trial of intranasal foralumab in nonactive secondary progressive multiple sclerosis, and we refer to that as NASPMS.
I'm Ivor Elrifi. I'm the CEO of Tiziana Life Sciences. And today, I have with me a number of our key opinion leaders. Before I get there, I have to just dispense with some legalities. So please, because we're a publicly traded company, read the forward-looking statements and govern yourselves accordingly. Let me introduce the presenters. The first is Dr. Tanuja Chitnis. Tanuja is the principal investigator of the INFORM-MS trial.
She's a Professor of Neurology at Harvard Medical School and Brigham and Women's Hospital. We also have with us Dr. Tarun Singhal. Tarun is the Founding Director of the NeuroPET program at the Ann Romney Center for Neurologic Diseases, which is associated with the Brigham and Women's Hospital and Mass General Brigham. And he is also an Associate Professor of Neurology at Harvard Medical School.
And lastly, but not least, of course, is Dr. Howard Weiner. Dr. Weiner is the Chair of Tiziana's Science Advisory Board. He's Robert Kroc, Professor of Neurology at Harvard Medical School, and he's the Co-Director of the Ann Romney Center for Neurologic Diseases at BWH. So without further ado, I will turn it over to the investigators to the key opinion leaders to discuss the INFORM-MS trial and the events that led up to it.
Howard, take it away.
So thank you very much. It's great to be here. I've spent my whole life working on multiple sclerosis from the time that there were therapies to when we first did immunotherapy to our B-cell therapies. And what's really important is if you look at the stages of multiple sclerosis, multiple sclerosis has evolved over time. When I started, there was no treatment for MS or relapsing disease. We now have very good treatments.
These are anti- B-cell therapies. But what we discovered is that people who -- I don't know, can you see my arrow here? Is that seen by anybody? No. No. What we discovered is people who have their relapses shut off, many of them become progressive. And that's now the major challenge in multiple sclerosis. And there's no -- although there's many FDA-approved therapies for relapsing disease, there are no therapies for nonactive secondary progressive disease. And there's a major unmet need. Dr. Chitnis, Dr. Singhal online will tell you of all the patients who come to our clinic are on the therapy and they say, well, the therapy is supposed to help, why am I getting worse?
And 25% become progressive and many are nonactive. Nonactive means there's no more attacks, no more MRI lesions. So it's a little silent in a way, but we discovered that you can see it by PET imaging, and you'll hear about that. Now another very important thing, and Dr. Chitnis has pioneered this work is that fatigue is a major symptom that impacts quality of life and daily function in MS. And one of the things we discovered quite to our surprise, but very exciting for us and the patients is intranasal foralumab helps fatigue. And you'll hear that in the INFORM-MS trial, we even saw it after 3 months.
So I spoke about the current therapies and many of the people we treated were on ocrelizumab and are still getting worse. And what's very exciting, and this comes out of work from my laboratory, is that the intranasal foralumab targets microglial-driven neuroinflammation. So what's going on in MS, in progressive MS is microglial inflammation. And there have been no trials that have targeted microglial inflammation in the way we've done it and certainly nothing as positive as what we've seen.
Next slide, please. So a big question is, how does nasal foralumab work? So foralumab is a fully human monoclonal antibody. It binds to the T cell receptor. One thing is that some people think, well, as you give it nasally, it goes into the brain. That's not how it works. It doesn't have to go into the brain. And in fact, it doesn't go into the brain. When you give nasal foralumab, one of the reasons we give it nasally is that the most powerful immune regulatory parts of the immune system are the gut and the nasal and lung because there, if you're exposed to the environment, you have to generate regulatory T cells.
And so foralumab, which binds to T cells, it binds to it in the cervical lymph node. And what it does is it specifically activates regulatory cells. Now why does it do it? That gets into some immunology. It has to do with the other cells that are in this particular area, but it's known that, that's why you get regulatory cells.
Now most of you know that Nobel Prize was just awarded to Shimon Sakaguchi for describing regulatory cells called Tregs. And he got it. It was a basic discovery. He got it because it's so important in modulating the immune system and treating disease. In fact, I had dinner with him in Japan the day before he was -- the night before he won the Nobel Prize and then spoke to him here. He loves our approach of inducing Tregs by giving nasal anti-CD3. And there aren't any other ways as simple and direct as ours to induce Tregs.
So we induce the Tregs in the cervical lymph node. They go into the bloodstream, okay? And after they go in the bloodstream, they come back into the brain because regulatory T cells and T cells traffic throughout the body, they go into the brain, and that's where they dampen the microglial inflammation. And they do it by a cytokine or a chemical called IL-10, and we've shown that in animals. And so it's a very unique approach. We have enormous amounts of animal data and now clinical data, and we'll talk a little bit about it in terms of the clinical effects, the dampening of microglial activation and affecting the immune system.
So it was very exciting for all of us in the MS center to have some of our patients who are just doing terrible who went on the nasal foralumab and then we're doing better. So I'll turn it over to the next slide. And we'll turn it over to Dr. Chitnis who was in charge of our expanded access trial. I'll say one word before Dr. Chitnis starts. We didn't know whether this would work or not, but I had a patient that was doing very bad even though they were on ocrelizumab. We got permission from the FDA to give nasal foralumab. We treated the patient. And after 3 months, Dr. Singhal comes running up to my lab, "Oh my God, Howard, you're not going to believe this." Complete decrease of microglial activation.
Then under Dr. Chitnis' leadership, we went into an expanded access trial. She'll tell you about it, where we treated a number of patients and saw very positive effects. And then the big question is, can we replicate that in a blinded multicenter trial, and that's what we found in this trial. So I'm going to turn it over to Dr. Chitnis and she'll tell you about the expanded access trial.
Great. Well, thank you, Howard, and welcome to everyone who is viewing this or participating. So I will echo Howard's words and just say that nonactive secondary progressive multiple sclerosis is one of our major unmet needs. We have no treatments for this form of disease. Patients continue to have progression, disability worsening, and it's a really difficult thing to see as a physician taking care of these individuals.
And so I was very excited when Howard showed me the animal data from his laboratory showing that this anti-CD3 molecule when given intranasally does induce to regulatory cells that go into the brain and dampen microglial activation. And so this has been shown on multiple mouse studies. And now our job was to think about how can we translate this into humans.
Before we started the expanded access study, we did do a Phase I study, which we will refer to throughout this presentation, and we tested 3 doses in that study. So a 10, 50 and 250-microgram dose. And from that Phase I study, because of the results in the 50-microgram dose, the middle dose, we decided to start dosing patients with the 50-microgram dose in an expanded access program. So as Howard mentioned, there was a very difficult patient who is having a very difficult time progressing and really wanted to try anything that we thought was promising. So we discussed starting intranasal foralumab, and he was our first patient in this program.
Next slide. So in this program, we started with our first patient. He demonstrated improvement. In fact, clinically, he started to stabilize and was no longer worsening within 3 months, 6 months, he continued to show this pattern, and that continued on for at least 1 to 2 years, and then he had to stop drug for other reasons. However, we were able to enroll additional patients, and we have dosed now 10 patients in this expanded access program, which were reported in this publication in a journal called Neurology, Neuroimmunology & Neuroinflammation. It's one of the top-ranked journals in neuro immunology and multiple sclerosis research.
So we reported in this publication on these 10 patients. So first of all, the drug was very safe. There were no toxicities. There was no treatment-related adverse events observed and no antidrug antibodies detected in the serum. The second thing that we observed, and I'm going to go to the box at the bottom is what we call the EDSS or the expanded disability status scale, that stabilized in all of our patients after 6 months of treatment.
Now that is a win actually for progressive multiple sclerosis because typically, this EDSS or disability score continues to worsen. And some of our patients after 12 months of treatment, so 3 out of 4 patients actually improved their EDSS score. And we measure this very carefully. We have a large MS center. We've been studying MS for over 25, 30 years, and we measure this very carefully.
On an anecdotal basis, patients also reported just they were feeling better, doing better, able to do more in their everyday lives and jobs. So that validated our findings in the EDSS scoring. We also found that fatigue improved in 7 out of 10 patients after 6 months of treatment. And this was quite substantial improvement. We measure fatigue using a scale called MFIS or Modified Fatigue Impact Scale. And this is a 21 question questionnaire. There are subscales to this MFIS questionnaire, and we were able to find that there was an improvement or reduction in fatigue in 7 out of 10 of these patients by at least a score of 4. Some of these patients improved by scores of 15 to even 20. But on average, the reduction was at least 4 to 6.
The change in fatigue or MFIS score by at least 4 has been determined to be clinically meaningful. Several publications speak to this, including Rooney published in multiple sclerosis journal. So we did see a meaningful improvement in fatigue. And then the last point is the question around why is this happening? How did we improve or how did we see reduction in these 2 major disability scores. This could be explained in large part by what was seen on the TSPO PET.
And I will turn it over in the next slide or 2 to Tarun to discuss the TSPO-PET results. But just the bottom line was that 8 out of 10 patients showed reduced inflammation or neuroinflammation after 3 months of treatment. And this is inflammation in the brain associated with microglial or activated microglia, which have been associated with progressive forms of MS. And this has been the really difficult thing to treat in multiple sclerosis is the neuroinflammation that's trapped behind the blood-brain barrier. And we found that there was a reduction in this type of inflammation.
Next slide.
All right. So as Dr. Chitnis mentioned, in the expanded access program, we saw a significant reduction in the PET imaging signal using F-18 PBR06, which is a radiopharmaceutical that targets a molecule called TSPO, which has been shown to represent the innate immune activation in the brain, which is the compartmentalized immune activation behind the closed blood-brain barrier. This immune activation is not readily visible on conventional MRIs, and that is why there is this need for this technique of TSPO PET.
And as you can see here in panels A and B, these are maps of abnormal voxels in individual patients using a Z-score approach, where an individual patient scan is compared to a group of healthy people. And on a voxel by voxel, a voxel is basically a volumetric pixel, we map out the extent of abnormality. And the brightness of the color represents the extent of abnormal signal that we see there. So in both panels A and B, you can see in the top row, which are different views of the brain, there is a lot of red, which means there were a lot of abnormal voxels in these patients.
And after treatment with 50 microgram of nasal foralumab for 3 months in the second row in both these panels, panels A and B, you see a reduction in all that red signal. And that kept on progressively decreasing in the last row in panels A and B at 6 months following treatment with 50 microgram of nasal foralumab, where you see that this red signal is significantly decreased. And when we analyzed all available patients in the expanded access program in panels C and D, you can see a statistically significant difference after treatment with 50-microgram nasal foralumab in the expanded access program.
Next slide.
Tarun, if I may interrupt just for 1 second, just to go back. Just to be clear for the audience, panels A and B are 2 different human beings, 2 different patients who have SPMS and the 3 different images you see across each row are different cross-sections of their brain. And as Tarun made clear, if you see less light, it means less neuroinflammation as you go down each row.
Yes, that's correct.
Sorry for the interruption, Tarun.
No, worries, Ivor. Next slide.
Yes. The other big question, if the nasal foralumab works, and we know in the laboratory, it works by inducing regulatory T cells and modulating immune function, we can take these cells out of the animals and study them, et cetera, et cetera. But the big question was, could we show a change in immune function in people treated with the nasal foralumab. And that's a big challenge and not something that's easily accomplished.
Many people are trying to modulate the immune function with various treatments, and it isn't easy to see it. But we saw really a very clear and dramatic effect on immune cells and immune function. This is work we did, work that Dr. Chitnis did. And the total picture is very complex. I'd love to show you all the different immune cells that change, but let me highlight 3 things.
#1, we increased regulatory T cells. And this is the central mechanism why this works. So this proves the theory works, and we could see it in people in terms of the enhancement of regulatory T cells. And when I told this to Dr. Sakaguchi, he loved this because he was trying to figure out a way to induce regulatory T cells. The other thing, #2, is that there's a decrease in cytotoxic T cells. Cytotoxic T cells are the cells that cause damage in the nervous system. And the nasal foralumab not only decreased regulatory T cells, but it decreased cytotoxic T cells.
And then the final point, we did spinal taps on these patients. We can't take brains out, et cetera, but we did spinal taps and did very careful analysis, and we saw a decrease of inflammation in the spinal fluid of the patients that we treated. It was really remarkable. And something else that doesn't say here, we not only found decreased inflammation, but there are some good proteins, proteins that help nerve cells grow like BDNF and those went up. So the immunologic findings totally validate what we saw clinically and by PET imaging.
And in other data, we looked at these changes in the blood and looked at the changes in the spinal fluid and Tarun was able to correlate the changes in the spinal fluid and blood with what he saw in PET imaging. So it puts it all together in a beautiful way. And this also now provides us with a way to measure immune function in all the other patients and diseases that we hope to use in nasal foralumab.
And this opened the way then for our double-blind study, we had all this positive result. We wrote up our paper. It got published. But this is open label, and it's very clear you have to prove even though it's very strong, you have to prove in a double-blind way that this is real. And this led to the INFORM-MS trial that Tiziana set up Tanuja as the principal investigator of and involved, I think, 8 centers. And we can show you that and how it validated and confirmed the expanded access program. Next slide.
Great. So I'll take it from here. So as Howard alluded to, we -- our next step was to set up this Phase IIa study. This is a placebo-controlled double-blind trial of intranasal foralumab in multicenter and nonactive secondary progressive MS.
Next slide. And so the study design is shown here, and we, in total, screened 67 patients, 48 were randomized to 3 arms, 18 were randomized to placebo, 19 to foralumab, 50 micrograms dose and 11 to 100-microgram dose. We -- it has been a bit challenging to enroll or was challenging to enroll nonactive SPMS patients and especially in the time frame that we had allotted ourselves. So we did choose to limit the number of patients enrolled in the 100-microgram arm and focus on enrolling in the 50-microgram arm, since that's where we had the most data -- successful data in our expanded access program on 10 and now 14 patients as well as our Phase I study, which demonstrated that this was the best dose immunologically.
So we had a number of different readouts. Safety was assessed in all of our patients. We had PET scanning done in all of the patients at one site. And so you can see that most of the patients completed their PET scan pair. However, there were a few patients for various reasons or manufacturing technical issues could not complete the pair of PET scans. However, the majority -- the vast majority did. We also captured fatigue scores or MFIS scores in almost all patients, except for one and also our EDSS or disability scores in all patients. And there are many other secondary tertiary outcome measures that were also included, but these are really the 4 main outcomes that we were focused on. So safety...
And Tanuja, just so that people understand, a PET scan pair means a PET scan of the patient before they receive foralumab, we call that baseline and a PET scan at 12 weeks after 12 weeks of treatment of foralumab. That's what a PET scan pair is.
Perfect. And also to also confirm that this was a 3-month study. So we powered it. We based it on the expanded access results where we had seen results within 3 months on the PET scan in particular. And so we based this trial design on our expanded access program. And you can imagine, 3 months is a very limited amount of time to show a difference.
However, we did. So next slide. So the major top line results, Tarun will go into the PET scan results in much more detail. But on this TSPO PET, which measures microglial activation, there was a significant reduction in the TSPO PET signal in the 50-microgram arm, which was sufficiently powered to show a difference. In the exploratory arm, the 100 micrograms, we had only 11 patients compared to the 18 or 19 in the other arms. And so we did not see a significant difference.
And we also thought that this might be partially due to the limited number of patients, but possibly also due to the fact that the 50-microgram dose had in many studies shown to be the better dose and has that sweet spot of immune modulatory effects. And just sort of speaking to the immunology of this, you want to give enough of a boost to the regulatory cells, too much of a signal or boost could also induce cell death. So we don't want to do that, and that could be a potential reason why the 50-microgram dose was really the sweet spot -- we also noted a clinically meaningful difference in fatigue or the MFIS score of delta 6.17 in the 50-microgram arm and delta 7.18 in the 100-microgram arm.
And so this was a within paired analysis. So within each dose group, we looked at the difference between baseline and 12 weeks and showed this reduction in fatigue scores. It was not an ANCOVA analysis across the entire 3 cohorts, however, just within-group analysis. We were not sufficiently powered to look at an ANCOVA type of analysis that would have required several hundred patients per arm. But despite that fact, even within these small numbers, we showed a significant reduction in the fatigue scores, which mimicked what we showed in our expanded access program with a mean difference of about 6 to 7 reduction in MFIS scoring.
Sort of as a background as well, fatigue is a major unmet need in progressive or in multiple sclerosis in general, and it's particularly prevalent in progressive multiple sclerosis. And there is much more evidence now indicating that fatigue, in fact, is both a precursor of progression and shares a lot of the same immune mechanisms, including activated microglia.
So the last point that I'll bring up was that the study drug at both doses was safe and well tolerated. There were no drug-related SAEs and patients did very well, and there were no discontinuations due to SAEs or AEs in this trial. So I think that is really the summary, top line results. And of course, there's much more analysis to be done on some of our tertiary outcome measures, including the immunology. Next slide to Dr. Singhal.
Yes. Thanks, Dr. Chitnis. So as Dr. Chitnis mentioned, in the INFORM MS study, neuroinflammation was statistically significantly reduced. When we looked at all patients with the analyzable scans, which was [ NO 40 ] on ANCOVA analysis, which takes into account all the 3 groups together, the F-18 PBR06, TSPO PET demonstrated a significant reduction in globally normalized white matter signal measured by this index called SUVR or Standardized Uptake Value Ratio with a p-value that was lower than 0.05. It was 0.0168 after 12 weeks of treatment with 50 microgram of nasal foralumab as compared to the placebo.
And that result was statistically significant. And you can see below in the 2 panels, one labeled as nasal foralumab and the other labeled as placebo. These are 2 different patients. These are examples of those same Z-score maps that had shown a statistically significant reduction in the EA or the expanded access program, and these are represented here with a similar color scale, where red represents more abnormal voxels in a given patient. And you can see on the left-hand side in the nasal foralumab panel, before treatment, there was all these areas of red, which means that there was a high amount of innate immune activation or inflammation in this particular individual.
And after treatment with 50 microgram of nasal foralumab, you can see that we replicated our results that we saw at our center with the reduction in the inflammation after treatment with nasal foralumab 50-microgram dose. On the other hand, this is a patient on the right side, which was treated with placebo, had this abnormal signal at baseline. And after treatment with placebo for 12 weeks, there was an increase in this signal. So after controlling for other variables when we look at patients that we had in our EA program and we compare it with our data in the Phase II, we replicated the finding of reduced microglial activation after treatment with foralumab.
And in fact, the findings were enhanced by this placebo comparison where we had this evidence of increase in placebo arm after adjusting for the other covariates, and that was statistically significantly different or better outcomes with the nasal foralumab treatment as compared to placebo. So this is a great replication of our findings in the expanded access program on this Phase II in a double-blind, randomized placebo-controlled study. Next slide. Dr. Chitnis.
Dr. -- yes. So this is now a close-up of the fatigue score. So this is the MFIS total score. And just as a quick reminder, this is a 21-point questionnaire that the patients answer. And you can see in the 50-microgram dose, there was a reduction by 6.17 in the fatigue score. In the 100-microgram dose, a reduction of 7.18, both were statistically significant within their own group.
However, in the placebo group, there was no change -- no significant change. As you can see by this p-value of 0.4, which is almost a coin toss and a really minimal reduction. So what does this mean? And what does a change in 6 or 7 points on the fatigue scale, what does it actually mean? So the publication on the right is the one that I was referring to showing that a reduction of at least 4 points on the fatigue scale is clinically meaningful. And so they compare this to quality of life measures. They compare this to other outcomes in patients and found that this change in 4 is clinically meaningful.
So these results surpass that. And this also -- anecdotally, I can also recount that patients in the expanded access program had a similar reduction on fatigue scores, and they would tell me things like, I feel so much better. I can get on with my day and do things that I couldn't do before. I can work for hours longer than I used to work, and it really does translate. So we think that we see replication of our open-label study. We see reduction in fatigue here, and this is clinically meaningful. Next slide.
And I'll talk to this. So sorry for the duplication here, but we just wanted to make sure everybody got the message. So the message is in the Phase II placebo-controlled double-blind study, the drug in our hands, we observed that it was safe at both doses. We believe this is the first noninvasive anti-CD3 therapy that has been shown to be safe and well tolerated. And by noninvasive, we mean you don't have to take it IV, you can inhale it nasally.
Our primary endpoint, so that's the endpoint that you say to the FDA, you're going to meet was a reduction in microglial activation as measured by PET. We met that endpoint at 50-microgram dose, which was the dose that you've heard was the dose we have the most experience with. And then immunologically, we had the highest expectation or hope for and the p-value is 0.0168. So just to remind you, a p-value of P 0.05 or less means that you have -- there's a 95% likelihood it's not random, that is there's a real effect here. So we had a very good p-value.
And then lastly, fatigue was a secondary endpoint. And as Dr. Chitnis pointed out, we didn't power the study, meaning we didn't enroll and we didn't intend to enroll enough patients to have statistical significance of the secondary endpoints. So we've needed 10x as many patients. But nonetheless, within the arms, we actually saw that fatigue was improved meaningfully according to the paper that Dr. Chitnis presented, meaningfully from the beginning of treatment duration to the end of treatment duration. So we are thrilled with the data.
Next slide, please. SPMS is not the only thing that we have going on in the clinic. We also have a Phase II trial in a disease called multiple system atrophy. That data will read out in the next 3 to 4 months. We also have a study in Alzheimer's. It's a double-blind, placebo-controlled study. And that trial is fully enrolled. We're waiting for the patients to receive their final dose, and we expect top line data in that study in Q1 of '27. So 3 to 4 months away, 5 months away, a very short period of time.
And then finally, we have -- we were accepted into a very prestigious program called ALS MyMatch is the consortium of the centers of ALS Clinical Excellence in the United States. There are only 2 companies in the program, of which we are one. We dosed our first patients in that study just a few months ago, and we expect that trial will read out in 2027 for sure. So if I could go to that -- and we have ongoing programs that are expanded access or open-label extension for the patients who are in the SPMS trial.
Next slide. I just wanted to leave you before we go to questions with 2 slides. I don't want to steal Dr. Singhal's thunder here, but we have seen the same trend in reduction in microglial activation as measured by TSPO-PET in Alzheimer's. These are images of a patient's brain, 3 different cross-sections. But if you look at the top row, it's just 3 different cross-sections of a patient's brain. And if you compare the top row and the bottom row, you can just visually look and see there's a reduction in neuroinflammation as measured by PET. That's in Alzheimer's. So more to come on that in 3 months or so.
Next slide. And in multiple system atrophy, which is a terrible disease, which has no approved therapy and is fatal. Again, we have data in patients now where after 3 or 6 months on foralumab, there's a significant reduction in neuroinflammation. And again, we'll be presenting more data on that in the next 6 months or so. But the take-home message is the mechanism of neuroinflammation is common across many neuro disorders, and we are seeing a reduction in neuroinflammation with nasal foralumab.
Next slide, please. So I think I'll open it up to questions and Dr. Weiner, Chitnis and Singhal will be answering the questions. So fire away, please.
We will now take the first question from the line of Tom Shrader from BTIG.
2. Question Answer
Very helpful. It's new stuff for all of us, so we appreciate the detail. I guess the question is really for Dr. Singhal, but I'm glad to have all the input. The only wrinkle to this trial, the fatigue data is unrelentingly positive at both doses and the TSPO data doesn't follow in the high dose. I'm curious how noisy is the TSPO imaging? It's a complicated scan. And did the patients that got clinical benefit but didn't seem to show a good scan, were their cytokine markers also less impressive? How does everything correlate?
And then the follow-up to that is, when would you expect to present patient-level data, did most patients see something in TSPO? How small a change can you see? I just -- I'm kind of looking for a little bit of intuitive background to your technique because we all know a little bit about it, but I don't think any of us really understand how much detail you can glean. So any detail and as I say, any other -- the experts, I'm glad to get your input.
Yes. So I think the key reason from a PET imaging perspective for the 100-microgram result is the sample size. So you know PET imaging is a very sophisticated and sensitive technique and has to be evaluated in a very careful and informed manner. And we have been studying this F-18 PBR06 PET for over 10 years now across diseases and came up with these approaches over the years. And in the expanded access program, for example, we used the Z-score approach, and we have done the global normalization approach before.
So overall, I think for the 100 microgram, the reason is in the lower sample size. And obviously, there's going to be more analyses, including cytokines and other markers with Dr. Chitnis and Dr. Weiner, which will provide more insight into it. Overall, I think we are replicating the results of the reduction in microglial activation as compared to the placebo, which we saw in the EA program. And when we look at our [indiscernible] scores, for example, at our centers, they're exactly the same.
It's like it's a very profound replication when you take care of a lot of other variabilities in terms of centers, et cetera. And the vast majority of patients, for example, at our center, they showed a reduction on treatment and on placebo, they showed an increase. So the PET imaging is known to have noise, but we do appropriate normalizations, and that has been a big challenge in the field, how to normalize the data. And that is why it requires all this experience to find out what are the determinants of that type of noise, and that's our current assessment of that data set.
Yes. This is Dr. Weiner. Let me say something you mentioned that between the 50 and 100. The higher the dose in general, when you do this, the less it tends to work. And I think that the -- the difference between the 50 and 100, we didn't have enough for the PET scan to know whether it works or not. We know the 50 works very well. We have very good immunology on the 50, and we now are going to be able to look at the immunology on the 100 as well.
It may be that the fatigue is more sensitive. It's a more global measure of the MS patient because it's a symptom. So I think that we can't say anything about it, but it all fits with what we've seen in terms of higher doses may not be as well tolerated, and we will be reporting on immunology comparing the 50 and the 100. But we -- this was exploratory. And we chose the 50 for this study in all our studies because that seems to be the right dose. So we'll see what comes out. But I wouldn't say that it's not consistent. I think it's that the fatigue may be more sensitive to changes that are going on.
Maybe I'll just add one point to all of this. So fatigue is a very specific symptom that relates to your awake network. So not all of your brain is involved in the mechanisms of fatigue. And in studies that Dr. Singhal has published previously, there are certain areas of the brain on microglial PET that are particularly associated with fatigue. So the substantia nigra, that's also involved in Parkinson's and the hippocampus are some of the areas.
So there is a fatigue network in the brain, and that is affected in MS. It's not all areas of the brain. So it may be just where the lesions happen to be and that fatigue was more sensitive. And on TSPO PET we're measuring inflammation in the entire brain. If there was a subscore that eventually might be done, then there might be better correlation with the actual fatigue network.
Just a follow-up. Do you think we would see data sort of at that level of image analysis from this trial? Or is that something for the future?
I'll let Dr. Singhal answer that. I mean I think eventually, it could be done, but it's just a matter of time.
And we'll be analyzing data more and more. There's no question about it. It's a very rich data set, and we'll be looking at it.
So this is Dr. -- just -- sorry, go ahead.
Yes. We'll look at the 100. We probably are not going to be doing a large number of patients comparing the 100 to the 50 to see whether it links exactly with that. We will have immunology data and some PET scan data on the small number of patients on the 100. But we have enormous data on the 50, et cetera. Ivor, you're going to say something?
I was going to say -- so Tom, stay tuned for additional data. Remember, this top line data is hot off the press. It's literally a week old or maybe slightly older than that, but it's not old. We're burning the midnight to crunch this data.
We will now take our next question from the line of Elemer Piros from Lucid.
Just to come back to the 2 doses, if we assume that the 100-microgram dose is over the top and as you surmise, would it be also possible that the fatigue scores because we have a limited number of patients in this dose group and since they are subjective, that they are less reliable or less quantifiable per se. And the issue is with the fatigue scores as opposed to the lower activity on the microglial activation? That would be my first question.
So I can start to answer that question. So you're really asking, is the fatigue score a reliable score and can we trust it? So I would say, yes, we saw a significant reduction within arm at both the 50 and 100-microgram dose in a randomized trial, multicenter. So this is blinded, randomized, multiple centers involved, and we saw a significant reduction.
So I do think that we can trust that result, and it is very consistent with our results from the expanded access program. So we saw, in fact, a 6- to 7-point reduction in the fatigue score in the expanded access program. So we're showing replicability and consistency now across of the 2 studies.
Thank you, Dr. Chitnis. Maybe the next question would be, have you been able to observe a patient level correlation between the magnitude of microglia reduction and fatigue improvement?
So that analysis is ongoing. That's a much larger analysis. And as Dr. Chitnis mentioned, we have to look at the subregions of the brain rather than like white matter, for example, that we have focused on and reported. So that analysis is ongoing, and we are also interested in learning about that.
And the last question would be about the future. How would you design a potentially pivotal trial? What sort of measures? No one really expected EDSS to change after 3 months. But would you start focusing on that type of measurement in a longer, maybe a 1-year -- 1 to 2-year trial?
So I can start to answer that question. So I think for a Phase IIb or Phase III trial, of course, we need a clinical outcome measure that's clinically meaningful. And there is a strong rationale for focusing on MFIS with the fatigue score as the pivotal measure. Another contender, of course, is the EDSS, EDSS score. And so one could measure these in several ways.
So the fatigue score, we've seen a significant reduction of at least 4 points or more in the 50 and 100-microgram dose. So it could be anchored on that change in a larger study. Another contender is both stability as well as potentially improvement on EDSS. And so in our expanded access program, we saw stabilization of the EDSS score in all of the patients over 6 months and an improvement in 3 patients out of 10 at the 12-month mark.
So there is also potential for using the EDSS, either stabilization and improvement or one or the other. And I think this is going to determine the sample size for the study. So there's strong data for one or more of those outcomes.
This is Dr. Weiner. You can also measure confirmed disease progression. It is another outcome measure because over time, these people get worse and the EDSS might get worse in some, but not in others. So another outcome measure is confirmed disease progression, but we have to look at everything in numbers, et cetera.
Elemer, if I may just add one more or a couple of more points. We will be working with the FDA and having an end of Phase II meeting to answer exactly that question as we develop a protocol for a pivotal trial. But I think the take-home message is the data here support advancement to a pivotal approvable trial.
That's point #1. We will be having a Phase II meeting with the FDA. And point three, when Dr. Chitnis says stabilization or improvement in EDSS, I hope the audience remembers that, that's a spectacular result that we saw from the expanded access program. And if you compare it with drugs that have not been approved, for example, Sanofi's tolebrutinib drug was not approved by the FDA in December of 2025 for liver toxicity exceeding the benefit of the drug in that trial, patients on -- in the treatment arm of the drug were getting -- the EDSS score was declining. It wasn't stabilized. It wasn't improving. So you're putting it in context, this data is spectacular all in, including the EA data.
There are no further questions on the phone at this time. I would like to hand over for webcast questions now.
So a question has come in. Do you anticipate use of foralumab in combination with other disease-modifying therapies such as ocrelizumab in individuals with SPMS or other forms of MS? And I will answer part of that question, and I'll turn it over, I think, to Dr. Weiner. But the answer -- simple answer is yes, we do anticipate using foralumab in combination with other disease-modifying therapies.
So for example, we have announced that we are going to be initiating a trial in Saudi Arabia at KAIMRC at their medical research center. And that trial will be a combination trial of foralumab and ocrelizumab in relapsing remitting patients, who aren't responding well to CD20 or ocrelizumab, a CD20 therapy alone. And Howard, maybe you can comment further.
Yes. It's now known that there's 2 components to MS. There's the inflammatory component and the progressive immune component. And Steve Hauser, who heads the Wild Institute at UCSF and was the developer of anti-CD20, he visited here last week, and he was very excited by the data and he says, Howard, you have to use this in combination. This needs to be given with anti-CD20 because it attacks a different part of MS.
So I was very encouraged to hear that. It's something that Dr. Chitnis has said, we're now going to be doing those combination therapies. So I would predict in the future that people will be put on combination therapy is used throughout medicine will be put on an anti-inflammatory drug like OCREVUS or anti-CD20 and will also then be put on a nasal foralumab. And the safety profile of nasal foralumab would go very well. So I think the answer to the question is yes, we will be trying combination therapy.
So another question has come in. In the INFORM-MS study, which is the Phase II placebo-controlled double-blind study, are your patients on prior disease-modifying therapies? If so, was there a washout period? And how long was the washout period before onboarding foralumab?
I can answer that question. So yes, the majority of our patients were on prior disease-modifying therapies, and they were not doing well. And that's why they wanted to enter this trial, of course, with their collaboration with their neurologist. And so some of these patients were on anti-CD20 antibodies like ocrelizumab or OCREVUS, others were on other treatments.
And there were standardized washout periods prior to starting in the foralumab trial. So typically, it's 6 months for the anti-CD20 antibodies and 1 to 2 months for the oral medications and other drugs. And this is fairly standard across MS trials.
And just to add to that, this is all -- the FDA is heavily involved in telling us what the washout period is. So that's all part of the protocol. Another question has come in says, will foralumab be a treatment for PIRA? And I think we've sort of pseudo answered this in the Saudi Arabia question, but Tanuja, maybe you can comment a little further.
Yes. So we know from the pivotal OCREVUS ocrelizumab trials that PIRA occurs in somewhere in the range of 30% at least of patients over at least a 2-year period, more frequently when you go to 5 years. So PIRA or Progression Independent of Relapses is a very important question in patients who are even treated with some of the strongest therapies that we have that shut off relapses.
So PIRA or progression does continue to occur. This is due to neuroinflammation that is in the brain trapped behind the blood-brain barrier that the anti-CD20 antibodies can't get to. And so we strongly believe that foralumab will shut down that type of inflammation and stop progression independent of relapses for PIRA in patients who are on anti-CD20s or on no other treatments or on other therapies as well.
Terrific. I think there's perhaps one more question coming in. The question says, beyond fatigue, did you observe any positive trends in disability progression, cognition, walking performance or other functional endpoints as in the EA program? I think the question means in the INFORM-MS trial, did we see any of those endpoints similar to the ones we saw in EA.
Right. So I mean, that's a fair question. However, just remember, the INFORM-MS Phase IIa trial was a 3-month study, whereas in the EA expanded access program, our first time point that we focused on was 6 months and then another was at 12 months. So it's really not quite a fair comparison. That being said, the EDSS score did not change in the INFORM-MS Phase IIa trial, again, at 3 months.
And we're analyzing all the rest of the outcome measures, but we did not see significant changes at least in the results that we've analyzed so far. But we would not really expect to because it's a very short study, 3 months, and it's quite remarkable that we saw a reduction in both the TSPO PET as well as fatigue scores at 3 months. Most drugs take many, many months, half a year or a year to take on their full effect.
Thank you. We just have maybe a minute left. So I would like to wrap up by saying thank you to our key opinion leaders. I would like to make a statement, which is I'll ask, is it fair for me to summarize the results of the INFORM-MS Phase II placebo-controlled double-blind trial as positive results that would support advancing to a pivotal approvable trial. Do each of you agree with that statement?
Yes.
Yes.
Yes. Yes. I agree 100%. No question.
Right. Again, we're -- for the listeners, thank you so much for listening. We really appreciate it to our key opinion leaders. We greatly appreciate you taking the time doing this. If anyone has questions, you can follow up with us directly after this webinar. Thank you so much for all attending. We really appreciate it.
Thank you very much.
Financial data from Tiziana Life Sciences PLC Sponsored ADR
Revenue
Revenue is the sum of all sales generated by a company, e.g. for its products or services.
Revenue (TTM) metric explainedDirect Costs
Direct costs are the costs incurred directly in connection with the manufacture of the product or service.
Gross Profit
Gross Profit indicates how much of the revenue remains in the company after deducting direct production costs. If the percentage share of sales is calculated, this is referred to as the gross margin.
Gross Profit metric explainedSelling and Administrative Expenses
Selling, general and administrative expenses (SG&A) include all expenses for marketing and sales as well as the general administration of the company.
Research and Development Expense
Research and development costs (R&D) provide information on how much the company invests in the research and development of its products. The costs are particularly interesting as a percentage of revenue and in comparison to direct competitors.
EBITDA
EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) is the company's earnings before interest, taxes, depreciation and amortization. The EBITDA margin is calculated as a percentage of sales.
Depreciation and Amortization
Depreciation represents reductions in the value of the company's assets (e.g. due to wear and tear on machinery).
EBIT (Operating Income)
EBIT (Earnings Before Interest and Taxes) is the company's profit before interest and taxes, also known as the operating income. The EBIT Margin is calculated as a percentage of sales at
.
Net Profit
Net Profit represents the profit or loss after deduction of all costs.
Net Profit metric explainedStocksGuide Premium
| Dec '25 |
+/-
%
|
||
| Revenue | - - |
-
100%
|
|
| - Direct Costs | - - |
-
-
|
|
| Gross Profit | - - |
-
-
|
|
| - Selling and Administrative Expenses | - - |
-
-
|
|
| - Research and Development Expense | 10 10 |
97%
97%
-
|
|
| EBITDA | -21 -21 |
33%
33%
-
|
|
| - Depreciation and Amortization | 0.23 0.23 |
92%
92%
-
|
|
| EBIT (Operating Income) EBIT | -21 -21 |
34%
34%
-
|
|
| Net Profit | -18 -18 |
55%
55%
-
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Tiziana Life Sciences PLC Sponsored ADR directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Tiziana Life Sciences PLC Sponsored ADR Stock News
Company Profile
Tiziana Life Sciences Plc is a biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. Its lead product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody. The company was founded by Gabriele Marco Antonio Cerrone on November 4, 2013 and is headquartered in London, the United Kingdom.
StocksGuide Premium
| Head office | United Kingdom |
| CEO | Mr. Elrifi |
| Employees | 10 |
| Founded | 1998 |
| Website | www.tizianalifesciences.com |


